Galderma’s phase III OLYMPIA 1 data published in JAMA Dermatology demonstrate that nemolizumab improves core signs and symptoms of prurigo nodularis Press release
Celebrating 25 years of Sculptra®: new data and recent approval in China cements Galderma’s leadership in regenerative biostimulation Press release
ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) Press release
EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations Press release
Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance Press release
Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence Press release
Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets Press release
Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries Press release
